NCT04998786View on ClinicalTrials.gov

"A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

January 1, 2030

Study Completion Date

January 1, 2030

Conditions
Multiple Myeloma at First Relapse
Interventions
DRUG

Ixazomib

Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress

DRUG

Iberdomide

Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress

DRUG

Dexamethasone Oral

Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22

Trial Locations (21)

Unknown

CHR, Annecy

CH de la cote basque, Bayonne

CHRU Hopital Haut Lévêque, Bordeaux

CHU, Caen

CHU, Clermont-Ferrand

CHRU, Dijon

CHD les Oudairies, La Roche-sur-Yon

CHRU Lille, Lille

CHU, Limoges

CH Lyon Sud, Lyon

CHRU, Nancy

CHU, Nantes

Hopital de l'archet, Nice

CHU Henri Mondor, Paris

Hopital St Antoine, Paris

Hôpital Cochin, Paris

University Hospital, Poitiers

CHRU, Rennes

ICANS, Strasbourg

CHU, Toulouse

CHRU Bretonneau, Tours

All Listed Sponsors
lead

Nantes University Hospital

OTHER